{"meshTags":["Aromatase Inhibitors","Axilla","Breast Neoplasms","Chemotherapy, Adjuvant","Female","Holistic Health","Humans","Lymph Node Excision","Mastectomy","Neoplasm Recurrence, Local","Patient Care Team","Radiotherapy, Adjuvant","Risk Factors","Selective Estrogen Receptor Modulators","Tamoxifen"],"meshMinor":["Aromatase Inhibitors","Axilla","Breast Neoplasms","Chemotherapy, Adjuvant","Female","Holistic Health","Humans","Lymph Node Excision","Mastectomy","Neoplasm Recurrence, Local","Patient Care Team","Radiotherapy, Adjuvant","Risk Factors","Selective Estrogen Receptor Modulators","Tamoxifen"],"genes":["aromatase"],"publicationTypes":["Journal Article","Review"],"abstract":"This seventh article in our series on breast disease will focus on what is new in the management of invasive primary breast cancer. Up-to-date information on the key aspects of breast cancer management is presented, including descriptions of the new technique of sentinel lymph node biopsy and the new hormone treatment, aromatase inhibitors. Current trends in surgery for breast cancer and the adjuvant treatments of chemotherapy and radiotherapy are also discussed.","title":"Management of early breast cancer--the current approach.","pubmedId":"16184208"}